Compare Revvity Inc (RVTY) vs Ryanair Holdings plc (RYAAY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Revvity Inc vs Ryanair Holdings plc — how do they compare? Revvity Inc trades at $116.28 (market cap $12.91B), while Ryanair Holdings plc trades at $59.5 (market cap $29.63B). The key difference: Ryanair Holdings plc is far larger — about 2.3× Revvity Inc's market cap, and Ryanair Holdings plc pays the higher dividend (1.51%). Which is the better fit depends on your goals.
| RVTY | RYAAY | |
|---|---|---|
Market Cap | $12.91B | $29.63B |
Sector | Technology | Industrials |
52-Week High | $117.75 | $73.82 |
52-Week Low | $82.26 | $53.24 |
Enterprise Value | $15.23B | $26.61B |
Dividend Yield | 0.24% | 1.51% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RVTY trades at $116.10, up 0.07% on the day, with a bullish technical signal and strong earnings beats in recent quarters. The company reported Q2 2026 EPS of $1.41, surpassing the $1.21 estimate, and raised its full-year outlook due to robust diagnostics demand. Revenue remains steady around $2.9 billion, with a net income margin of 8.16%. Analyst consensus is a Buy with a $120.50 price target, and recent news highlights product launches like the SuperFlex prenatal system and high-throughput TB testing platform.
The outlook for RVTY is positive, supported by earnings momentum and strategic innovations, but investors face risks from high valuation multiples and competitive pressures in the healthcare sector. The stock's proximity to its consensus target suggests limited near-term upside, requiring careful monitoring of execution against raised guidance.
Ryanair Holdings (RYAAY) trades at $59.41, down 0.17% with bearish technical signals despite reasonable valuations (P/E 14.37). The airline reported mixed quarterly results with Q1 2026 beating expectations but Q2 2026 missing, while maintaining strong profitability (22.41% ROE) and a solid balance sheet with $3.96B cash. Recent news highlights operational challenges from lower fares and fuel costs, alongside strategic AI partnerships.
Outlook remains cautious due to near-term headwinds from fare pressure and geopolitical risks, but long-term prospects are supported by industry consolidation potential and strong financials. Analyst consensus is bullish (62.5% Buy ratings), viewing current weakness as overdone. Key risks include fuel price volatility and competitive dynamics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →About Ryanair Holdings plc
Ryanair is the leading airline group by passenger numbers in Europe. The company employs a low-cost no-frills model to offer low fares to leisure customers on short-haul intra-European routes. In 2020, the most recent pre-pandemic fiscal year, the company carried 149 million passengers, utilizing a fleet of 467 Boeing 737 aircraft across its 1,800 routes. To keep costs low the company serves predominantly lower-cost secondary airports. The company generated sales of EUR 8.5 billion in fiscal 2020.
Read more on RYAAY →
